相关实验视频

Updated: Jan 18, 2026

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

由阿瓦特朗波巴格诱导的急性心肌梗塞:一个病例报告

Gou Junqi¹, Liu Chaohui¹, Lang Mingjian¹

¹Department of Cardiology, Geriatric Diseases Institute of Chengdu/Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, China.

Frontiers in pharmacology

|September 12, 2025

概括

阿瓦特罗姆波帕格 (Avatrombopag) 是一种血栓形成素受体激动剂 (TPO-RA),可在免疫血栓缩 (ITP) 患者中引起急性心肌梗塞 (AMI). 在TPO-RA治疗期间,仔细评估血栓风险和血小板监测至关重要.

科学领域:

血液学血液学血液学
心脏病学心脏病学
药理学药理学是指药理学的学科.

背景情况:

阿瓦特罗姆波帕格是一种用于免疫性血栓缩症 (ITP) 的血栓聚素受体激活剂 (TPO-RA).
TPO-RA携带血栓形成的风险,急性心肌梗塞 (AMI) 是一个报告不足的不良事件.
这一案例凸显了阿瓦特罗姆波巴格与冠状动脉血栓形成之间的潜在联系.

研究的目的:

报告一种ST升高心肌梗塞 (STEMI) 的病例,该病例发生在患者中,该患者接受了ITP的阿瓦特朗波巴格治疗.
为了强调与阿瓦特罗姆巴格治疗相关的血栓风险.
为了强调在TPO-RA治疗期间风险评估和血小板监测的重要性.

主要方法:

一个58岁的女性患有类固醇耐火性ITP的案例报告.
对临床表现,实验室值和诊断结果的分析 (冠状动脉血管学).
对治疗干预措施和患者结果的审查.

主要成果:

患者在启动avatrombopag单一治疗后五天就出现了STEMI.
冠状动脉扫描显示了急性血栓性阻塞,成功地用血栓吸收治疗.
血小板数量通过avatrombopag正常化,但在停止治疗后复发,需要重新开始服用阿司匹林.

结论:

单一治疗Avatrombopag可以导致快速冠状动脉血栓形成,即使在没有传统心血管风险因素的患者中也是如此.
在TPO-RA治疗期间,预防性抗血小板治疗和维持血小板计数在50-150 × 10^9/L之间至关重要.
在启动TPO-RAs之前进行血栓风险评估对于患者的安全至关重要.

关键词:

剧烈的心肌梗塞急性心肌梗塞这就是Avatrombopag.冠状动脉血栓形成的冠状动脉血栓免疫性血小板减少症.血栓形成素受体激活剂

更多相关视频

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

相关概念视频

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...